Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes

Mark E. Molitch, Amanda I. Adler, Allan Flyvbjerg, Robert G. Nelson, Wing Yee So, Christoph Wanner, Bertram L. Kasiske, David C. Wheeler, Dick De Zeeuw, Carl E. Mogensen

Research output: Contribution to journalArticlepeer-review

141 Scopus citations

Abstract

The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout The world, due primarily to The increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced The proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), The sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in The management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of The renin-angiotensin-aldosterone system; and lipid management.

Original languageEnglish (US)
Pages (from-to)20-30
Number of pages11
JournalKidney international
Volume87
Issue number1
DOIs
StatePublished - Jan 3 2015

Bibliographical note

Funding Information:
This conference was sponsored by KDIGO with support from Biocon. This work was also supported in part by the Intramural Program of the National Institute of Diabetes and Digestive and Kidney Diseases.

Funding Information:
DdZ declared having served as a consultant for and received honoraria (to employer) from Abbott, AbbVie, Astellas, ChemoCentryx, Johnson & Johnson, Merck Sharp & Dohme, Pfizer, and Reata. CEM declaring having received speaker honoraria from Merck Sharp & Dohme. MEM declared having received consultancy fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, and Novo Nordisk, and research funding from Bayer, Novartis, and Novo Nordisk. CW declared having received speaker honoraria from Astellas (Japan), Pfizer, Merck, and Merck Sharpe & Dohme. DCW declared having received consultancy fees from Abbvie, Amgen, Astellas, Baxter, F Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Otsuka, and Vifor; research funding from AstraZeneca/British Heart Foundation, Kidney Research UK, Medical Research Council, Healthcare Quality Improvement Partnership; honoraria from Amgen and Otsuka. AIA, AF, BLK, RGN, and W-YS reported no relevant disclosures.

Publisher Copyright:
© 2015 International Society of Nephrology.

Keywords

  • Albuminuria
  • blood pressure
  • diabetic kidney disease
  • glycemic control
  • lipid management

Fingerprint

Dive into the research topics of 'Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes'. Together they form a unique fingerprint.

Cite this